Reporting macrolide-resistant <i>Mycoplasma pneumoniae</i> : a diagnostic obligation?

ABSTRACT Macrolide-resistant Mycoplasma pneumoniae (MRMP) is increasingly detected worldwide, with increasing prevalence even in the United States. Detection of resistance within M. pneumoniae has meaningful clinical and stewardship implications. Resistance is most commonly mediated by point mutations within 23S rRNA and can be reliably identified by molecular assays, not just on isolates butalso on primary respiratory samples like swabs. Multiple studies associate macrolide resistance with prolonged fever, delayed clinical response, increased healthcare utilization, and greater antibiotic exposure due to delay or treatment failure. The detection of resistance can meaningfully influence the clinical course and overall patient outcomes. Though clinical disease is not any more severe in infections with resistant isolates, failure to report may perpetuate unnecessary macrolide use, leading to delay in transition to effective second-line agents (tetracyclines or fluoroquinolones when appropriate), and contribute to selective pressure. Beyond individual patient care, routine reporting provides valuable local epidemiologic data to inform empiric therapy, support outbreak recognition, and guide antimicrobial stewardship initiatives. Even so, a significant clinical gap remains as most commercially available diagnostic assays do not routinely detect or report resistance markers in Mycoplasma pneumoniae . Moreover, even among assays designed to detect resistance, performance can vary considerably with reduced sensitivity for organism detection and incomplete identification of key 23S rRNA mutations reported in comparative evaluations, as reported by Hénin N, Silvant A, Gardette M, Balcon C, Guiraud J, Bébéar C, Pereyre S, J Clin Microbiol 64: e0149125, 2026, https://doi.org/10.1128/jcm.01491-25 . Focused efforts are, therefore, needed to close existing diagnostic and reporting gaps to ensure resistance detection is more consistently integrated into routine clinical practice.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Microbiology
Published
2026-06-30
DOI
https://doi.org/10.1128/jcm.00164-26
Primary Topic
Pneumonia and Respiratory Infections
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reporting macrolide-resistant Mycoplasma pneumoniae : a diagnostic obligation?

Anisha Misra
Journal of Clinical Microbiology
Pneumonia and Respiratory Infections
article

Reporting macrolide-resistant Mycoplasma pneumoniae : a diagnostic obligation?

Anisha Misra
article en

Abstract

ABSTRACT Macrolide-resistant Mycoplasma pneumoniae (MRMP) is increasingly detected worldwide, with increasing prevalence even in the United States. Detection of resistance within M. pneumoniae has meaningful clinical and stewardship implications. Resistance is most commonly mediated by point mutations within 23S rRNA and can be reliably identified by molecular assays, not just on isolates butalso on primary respiratory samples like swabs. Multiple studies associate macrolide resistance with prolonged fever, delayed clinical response, increased healthcare utilization, and greater antibiotic exposure due to delay or treatment failure. The detection of resistance can meaningfully influence the clinical course and overall patient outcomes. Though clinical disease is not any more severe in infections with resistant isolates, failure to report may perpetuate unnecessary macrolide use, leading to delay in transition to effective second-line agents (tetracyclines or fluoroquinolones when appropriate), and contribute to selective pressure. Beyond individual patient care, routine reporting provides valuable local epidemiologic data to inform empiric therapy, support outbreak recognition, and guide antimicrobial stewardship initiatives. Even so, a significant clinical gap remains as most commercially available diagnostic assays do not routinely detect or report resistance markers in Mycoplasma pneumoniae . Moreover, even among assays designed to detect resistance, performance can vary considerably with reduced sensitivity for organism detection and incomplete identification of key 23S rRNA mutations reported in comparative evaluations, as reported by Hénin N, Silvant A, Gardette M, Balcon C, Guiraud J, Bébéar C, Pereyre S, J Clin Microbiol 64: e0149125, 2026, https://doi.org/10.1128/jcm.01491-25 . Focused efforts are, therefore, needed to close existing diagnostic and reporting gaps to ensure resistance detection is more consistently integrated into routine clinical practice.

Journal of Clinical Microbiology
Cleveland Clinic (US)
Good health and well-being
Openalex Percentile: Top 7%
Pneumonia and Respiratory Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.